CRITICAL INNOVATIONS LLC — Department of Defense SBIR Phase I: DHA213-009
CRITICAL INNOVATIONS LLC — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $250,000. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code DHA213-009 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $250,000
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase I
- Topic
- DHA213-009
- Solicitation
- 21.3
- NAICS
- —
- Place of performance
- CA
- Period
- 2022-03-25 → 2022-10-24
Description
The Defense Health Agency seeks to develop a novel wearable wound infection treatment delivery device capable of delivering treatment for the prevention of infection in a prolonged care setting. Critical Innovations, KARA & Associates, and consultants Loren Miller, MD, MPH, Captain David Tanen, MD, FAAEM, FACMT (USN, Ret.), and former Commander Denise Whitfield, MD, FACET (USN), have formed a team of experts to address this important need. During Phase I, our objectives will be to further advance the innovative Rx-Shooter product. This will include: 1) On-boarding program requirements, goals, and schedule; 2) Developing a proof-of-concept Rx-Shooter prototype that addresses applicable treatment requirements; 3) Performing benchtop testing on the Rx-Shooter to demonstrate feasibility; 4) Maintaining and compiling all regulatory compliance requirements while preparing for upcoming regulatory hurdles.